Dmitri Simberg, PhD, associate professor in the University of Colorado Skaggs School of Pharmacy, released a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. The study was published on July 1, 2021, in ACS Nano.
Tag: Glioma

New immunotherapy target discovered for malignant brain tumors
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
Study Identifies Exposure to Common Food-Borne Pathogen Linked to Rare Brain Cancer
A new study suggests a link between toxoplasma gondii (T. gondii) infection and the risk of glioma, a type of brain cancer, in adults. The report, appearing in the International Journal of Cancer, finds that people who have glioma are more likely to have antibodies to T. gondii (indicating that they have had a previous infection) than a similar group that was cancer free.
New Treatment Approach for a Common Glioma Subtype Shows Promise in Animal Models
A combination approach to treating a common subtype of glioma — which includes metabolic reprogramming and immunotherapy — led to complete tumor regression in 60% of study mice.
New Biomarkers for Glioma Treatment Response
Biomarkers using mass cytometry can assess patient response to an emerging vaccine for a specific pediatric brain tumor, according to a recent multi-center study published in the Journal of Clinical Investigation.

Ludwig Lausanne Study Charts the Immune Landscape of Multiple Brain Cancers
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.

Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy
An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.
Study Uncovers Unexpected Connection Between Gliomas, Neurodegenerative Diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer’s, as a biomarker for glioma development.